Leadership
GBM AGILE
About GBM AGILE
GBM AGILE Trial Sites
FAQs
Strategic Partners
REMAP-COVID
About REMAP-COVID
REMAP-COVID US Trial Sites
Ovarian CanceRx
News
Join Us
Contact
DONATE
< Back to News
Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system—lessons learned and recommendations
JANUARY 28, 2021 | BIOMED CENTRAL
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04997-6
Home
Leadership
About REMAP-COVID
REMAP-COVID US Trial Sites
Ovarian CanceRx
GBM AGILE
About GBM AGILE
GBM AGILE Trial Sites
FAQs
Strategic Partners
News
Join Us
Contact
DONATE